Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026

Late-breaking Phase 3 C-POST data provide longer-term survival outcomes for adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell carcinoma (CSCC) after surgery and radiation Final Phase 2 analysis explores potential of Libtayo before surgery (neoadjuvant treatment) for patients with resectable CSCC New data explore inhibition of Factor XI for cancer-associated thrombosis, a leading cause of cancer death, where bleeding risk limits use of anticoagulants TARRYTOWN, N.Y., Oct. 06, 20